Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Boehringer Ingelheim (Japan)

InstitutionResearch output, impact & collaborations

Boehringer Ingelheim (Japan) is a research organisation in Tokyo, JP. OpenAlex records 1,025 works and 87,040 citations for it. 296 researchers list it as their most recent affiliation.

1,025
Works
87,040
Citations
296
Researchers
2
Avg h-index

How has Boehringer Ingelheim (Japan)'s publication output changed over time?

ScholarIQpublication output · 2021–2026

Output grew0% over the shown period — from 1 works in 2021 to 1 in 2026.

1
3
2
1
2
1
202120222023202420252026

Who are the most-cited researchers behind Boehringer Ingelheim (Japan)?

ScholarIQtop researchers by citations
1
Satabdi Chatterjee · Chronic Kidney Disease and Diabetes
11 works43 citations

What are the most-cited papers on Boehringer Ingelheim (Japan)?

ScholarIQmost cited works
Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
Gregory A. Nichols, Efrat L. Amitay, Satabdi Chatterjee, Dominik Steubl
Kidney360. 202316 CitationsOPEN ACCESS
HSD80 Evaluation of Methotrexate Based Combinations in Rheumatoid Arthritis Patients: Results from a U.S. Administrative Claims Database
Yuying Huang, Shreya Agarwal, H Chen, Magnus L. Johnson, Satabdi Chatterjee, RR Aparasu
Value in Health. 20220 CitationsOPEN ACCESS
HSD133 Factors Influencing Selection of First Add-on Disease-Modifying Therapy for Rheumatoid Arthritis after Starting Methotrexate
Yixuan Huang, Suneal Agarwal, H Chen, Magnus L. Johnson, Satabdi Chatterjee, RR Aparasu
Value in Health. 20220 Citations
The Effect of Cardiometabolic Comorbidities on Risk of Chronic Kidney Disease Incidence: A Longitudinal Cohort Study
Gregory A. Nichols, Moe H. Kyaw, Satabdi Chatterjee, Dominik Steubl, Assad Jaghutriz Benjamin
S26605106. 20220 Citations

How much of the research on Boehringer Ingelheim (Japan) is open access?

ScholarIQopen access share
40%OPEN ACCESS
Gold
30%
Green
0%
Hybrid
0%
Bronze
10%
Closed
60%

Related on ScholarIQ

Diabetes Treatment and Management
Top Topic
Drug Transport and Resistance Mechanisms
Top Topic
Pharmacogenetics and Drug Metabolism
Top Topic
Chemical Synthesis and Analysis
Top Topic
Drug Solubulity and Delivery Systems
Top Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Top Topic
470M+ articles · free account